STOCKS TELEGRAPH

Tag: CELZ

  • 3 Stocks That Could See Big Moves: Creative Medical Technology (CELZ), Cardiol Therapeutics (CRDL), Nexalin Technology (NXL)

    3 Stocks That Could See Big Moves: Creative Medical Technology (CELZ), Cardiol Therapeutics (CRDL), Nexalin Technology (NXL)

    The biotechnology industry remains characterized by a steady flow of research-driven updates, including trial expansions, protocol refinements, and regulatory communications. Each of these elements can contribute to shifting expectations around a therapy’s future viability. As companies move deeper into late-stage studies, the market increasingly weighs the probability of success against the remaining development risk.

    Creative Medical Technology Holdings Inc (CELZ)

    Creative Medical Technology Holdings Inc (NASDAQ: CELZ) started the day on May 08, 2026, with a 0.87% price increase to $2.31. During the day, the stock rose to $2.38 and sank to $2.10. Taking a long-term approach, CELZ posted a 52-week range of $1.50-$6.25.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 66.83%. Meanwhile, its Annual Earnings per share during the time was 66.83%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 37.70%. This publicly-traded company’s shares outstanding now amount to $3.70 million, simultaneously with a float of $3.66 million. The organization now has a market capitalization of $8.54 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to expand its cardiovascular development platform by targeting inflammatory heart diseases with limited treatment options. Beyond recurrent pericarditis, the company is building clinical evidence in acute myocarditis, a serious condition that can lead to long-term cardiac complications and currently lacks targeted therapies.

    Market Momentum

    As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume reaching 578,846 shares compared to an average volume of 686,648 shares. The company maintains a market capitalization of $147.418M and a beta of 0.43, reflecting relatively stable trading characteristics for a clinical-stage biotech company. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 highlights substantial upside potential tied to future clinical execution.

    Clinical Expansion: ARCHER Study

    Cardiol’s Phase II ARCHER study evaluated CardiolRx™ in patients with acute myocarditis, a condition involving inflammation of the heart muscle that can progress to heart failure or arrhythmias. The study demonstrated reductions in cardiac inflammation along with structural improvements, including decreases in left ventricular mass, an important marker associated with cardiac remodeling and recovery.

    Scientific and Strategic Relevance

    The recent announcement that CardiolRx™ Phase II pericarditis results will be published in the Journal of the American Heart Association adds broader scientific credibility to the company’s anti-inflammatory platform. Positive findings across multiple inflammatory cardiac conditions may strengthen confidence in the therapeutic potential of CardiolRx™ beyond a single indication.

    Outlook

    As Cardiol advances development across multiple cardiovascular diseases, successful clinical validation in myocarditis could meaningfully expand the company’s long-term commercial opportunity and reinforce its broader pipeline strategy.

    Nexalin Technology Inc (NXL)

    As of May 08, 2026, Nexalin Technology Inc (NASDAQ: NXL) got off with the flyer as it spiked 2.44% to $0.35. During the day, the stock rose to $0.36 and sank to $0.35. Taking a more long-term approach, NXL posted a 52-week range of $0.33-$2.00.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -1.42%. Meanwhile, its Annual Earnings per share during the time were -1.42%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 30.00%. This publicly-traded company’s shares outstanding now amount to $20.58 million, simultaneously with a float of $16.33 million. The organization now has a market capitalization of $7.25 million.

  • Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance

    Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance

    Presently in the current trading session, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is experiencing a notable surge, marking a 22.80% increase to $5.00 as per the latest update. This uptrend in CELZ stock correlates with the regulatory clearance obtained for a novel pharmaceutical product by the company.

    The U.S. Food and Drug Administration (FDA) has designated CELZ-101, often referred to as ImmCelz, as an orphan drug as publicly disclosed by Creative Medical Technology (CELZ). This innovative therapy aims to shield recipients of pancreatic islet cell transplants against allograft rejection.

    For people with fragile Type 1 diabetes, a condition characterized by erratic fluctuations in blood glucose levels, it is a significant breakthrough. CELZ-101, alternatively termed as Supercharged Treg Biologic Immunotherapy (ImmCelz), epitomizes a cutting-edge paradigm in personalized healthcare, leveraging the patient’s own regulatory T cells (Tregs) to counter autoimmune and alloimmune responses that may jeopardize insulin-producing cells.

    This groundbreaking therapy is rooted in a proprietary methodology not only amplifying Tregs but also augmenting their efficacy, promising a viable avenue to diminish the necessity for lifelong immunosuppressive measures. The conferment of Orphan Drug Designation by the FDA for CELZ-101 underscores the unwavering dedication of the company towards pioneering therapeutic modalities.

    This pivotal achievement catapults the endeavor closer towards offering a sustainable resolution for individuals contending with the persistent challenges of brittle Type 1 diabetes, hallmarked by erratic glycemic fluctuations. It is in consonance with CELZ’s overarching mission to enhance the quality of life for patients through the vanguard of regenerative medicine.

    The advancement of CELZ-101 marks a significant stride in the domain of cell-based immunotherapy, addressing the imperative requirement for more efficacious interventions in brittle Type 1 diabetes by striving for operational tolerance in islet cell transplantation, potentially liberating patients from the onus of lifelong immunosuppression.

    This heralds the debut of the first orphan-designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes. The Orphan Drug Designation accorded by the FDA accentuates the potential of CELZ-101 in fulfilling a substantial unmet need in averting allograft rejection during pancreatic islet cell transplantation, which recently garnered FDA approval.

    This designation confers numerous consequential advantages to bolster the progression of the therapy including tax incentives, exemptions from user fees, and the prospect of market exclusivity post-approval.

  • Creative Medical Technology Holdings, Inc. (CELZ) stock gained 19.75% in after-hours. Why?

    Creative Medical Technology Holdings, Inc. (CELZ) stock gained 19.75% in after-hours. Why?

    The stock of Creative Medical Technology Holdings Inc (CELZ) closed the recent trading session at $1.57, gaining 5.37% from the previous trading session. During the last check, the stock of CELZ soared in the after-market, gaining 19.75%.

    CELZ News

    CELZ filed form 8-K with the SEC earlier this month to report the employment agreements. CEO and CFO entered into an agreement regarding the base salary, with the company. According to the agreement, the base salary of Mr. Timothy Warbington, CEO, remains $0.33 million per year. While the base salary of Mr. Donald Dickerson, CFO, remains $0.30 million annually. Further terms of the agreement are

    • The employment agreement is for three years.
    • Each executive can get a 30% cash bonus of their base salary, per year.
    • Every Executive is qualified for a yearly grant of a choice to buy various shares of normal stock of the Company with a worth of 30% of the Executive’s base compensation.
    • In case of termination, the executive will be qualified for the payment of base compensation and yearly rewards for two years.

    On December 3, 2021, CELZ also announced the public offering of its 3.8 million shares at the total cost of $16 million, at a price of $4.13 per share. Moreover,  the company said that it has now exhibited early achievement in animal models and at present has a forthcoming Investigational New Drug Application recorded with the FDA.

    About CELZ

    Creative Medical Technology Holdings, Inc (CELZ) is a biotech organization that is occupied with the advancement of urology, orthopedics, and nervous system science utilizing adult stem cell therapies. CELZ stock has a market cap of $21.38 million. CELZ is propelling the way that organizations address different immunity issues. Its ImmCelz stage is intended to “reinvent” immune cells in stroke patients. The company was founded in 1998 and has its base in Phoenix, Arizona, United States of America (USA).

    Conclusion

    The COVID-19 pandemic has prodded widespread development across the sub-sectors of the medical care industry for a while now, making this an appealing industry for investors. Things are working out positively for CELZ stock regardless of the shortfall of any stock news. It would be intriguing to perceive how lengthy this pattern will stay as the stock market is exceptionally eccentric.